Standardized botanical evaluation, multi-origin comparative assays, and certified pre-clinical pipelines engineered for ANVISA RDC registration.
Brazil represents the most potent bio-pharmaceutical and personal care landscape in South America. However, reconciling domestic regulatory frameworks with commercial supply stability demands world-class analytical rigor.
Brazilian National Health Surveillance Agency (ANVISA) enforcement—specifically under RDC 26/2014 for phytotherapeutic medicines and RDC 243/2018 for dietary supplements—mandates batch-to-batch chromatographic fingerprints, heavy metal clearance, pesticide limits, and validated quantitative assays before registration dossiers are accepted.
Brazil's Law No. 13,123/2015 establishes strict benefit-sharing and traceability compliance on indigenous genetic heritage (Patrimônio Genético). Multinational and local companies face operational delays when formulating purely native species, making standardized foreign botanical actives and dual-source strategies essential for continuous production.
With the São Paulo and Rio de Janeiro metropolitan regions driving high consumer demand for metabolic balancing, cognitive performance, and sports endurance formulations, industrial brand owners require concentrated plant matrices with clinically substantiated bioactivity rather than unstandardized herbal powders.
China’s botanical extraction industry has undergone an unprecedented technological renaissance over the past decade. Integrating classical Traditional Chinese Medicine (TCM) phytochemistry with German and Swiss automated continuous chromatography, Chinese manufacturing hubs provide Brazil's industrial leaders with non-replicable commercial advantages:
Understanding why high-yield active content retention requires advanced bio-guided fractionation rather than simple water-alcohol decoction.
| Evaluation Parameter | Conventional Raw Material Supplier | MedGence Precision ODM/CDMO Framework | Brazilian Regulatory Impact (ANVISA) |
|---|---|---|---|
| Origin & Seasonal Screening | Single-source opportunistic collection without seasonal active tracking. | Multi-regional origin matrix screening across harvest seasons, parts, and maturity curves. | Prevents batch failures in assay concentrations under Farmacopeia Brasileira monographs. |
| Analytical Method Development | Basic UV spectrophotometry or generalized HPLC assays. | Validated HPTLC fingerprinting, chiral chromatography, UHPLC-ESI-MS/MS verification. | Guarantees effortless identification and avoids raw material adulteration audits. |
| Preclinical Evidence Package | Literature references only; no internal validation. | Full in-house In Vitro, In Vivo, acute/chronic toxicology (LD50), and mutagenicity data. | Accelerates safety validation dossiers required for novel food and drug applications. |
| Physical Bioavailability & Form | Hygroscopic crude powders with erratic dissolution. | Micro-encapsulated spray-dried powders, stabilized oils, pastilles, and free-flowing granulates. | Eliminates formulation failure during high-speed encapsulation and tableting in tropical climates. |
Verifiable scientific throughput executed in cGMP pilot facilities and joint manufacturing networks across China.
Years Phytomedicine R&D
Scientific Researchers
Monographs & Processes
Hospital Drug Registrations
From anti-pollution dermo-cosmetics to cardiovascular functional dietary formulations, our CDMO pipelines fit seamlessly into local production requirements.
Formulated specifically for Brazil’s intense solar exposure and high-humidity climates. We produce non-phototoxic, high-antioxidant polyphenol fractions that remain stable in emulsions without oxidizing, tested via full in vitro cellular assays on human dermal fibroblasts.
Customized botanical active concentrates engineered for rapid absorption. Backed by animal study proof-of-concept dossiers demonstrating reduction in postprandial glucose spikes, ideal for brands expanding under Brazil's expanding functional food regulations.
Supporting Brazilian pharmaceutical groups seeking registered phytotherapy lines. We provide comprehensive chemistry, manufacturing, and controls (CMC) packages along with Phase I to Phase IV clinical study protocols and data packages.
Answers for Chief Scientific Officers, Regulatory Affairs Specialists, and Strategic Sourcing Directors operating in Brazil and global markets.
Select any capability below to examine technical methodologies, study designs, and custom OEM/ODM delivery options.
Whether you are preparing an ANVISA regulatory dossier, verifying active ingredient potency variations, or scaling commercial botanical batches, our senior scientists are ready to formulate your milestone plan.
Direct Scientific Team Email: [email protected] | Confidential Non-Disclosure Guaranteed